Use of Molecular Biomarkers Tests

EP: 1.Overview of Prostate Cancer

EP: 2.Challenges of PSA as a Diagnostic Biomarker

EP: 3.Role of Biomarker and Genetic Testing in Prostate Cancer Diagnosis

EP: 4.Emerging Serum, Urine, and Tissue Biomarkers in the Clinical Setting

EP: 5.High Risk Populations in the Development of Prostate Cancer

EP: 6.Risk Stratification in Prostate Cancer Patients

EP: 7.Challenges in Risk Assessment and Biomarkers in Treatment Recommendations

EP: 8.Influences and Challenges of Biomarkers on Treatment Selection

EP: 9.Efficacy of Biomarker Test Results

EP: 10.Biomarker Use in Patients on Active Surveillance

Now Viewing

EP: 11.Use of Molecular Biomarkers Tests

EP: 12.Integrating Biomarker Testing Into the Patient Care Journey

EP: 13.AI and the Future of Biomarkers in Prostate Cancer

EP: 14.Current Advancements in Biomarker Research

EP: 15.Unmet Needs and Treatment Gaps in Prostate Cancer

EP: 16.Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer

EP: 17.Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing

EP: 18.Tim Richardson, MD, on genetic testing in the era of targeted therapies

EP: 19.Paul Sieber, MD, on the future of genetic testing in prostate cancer

Video content above is prompted by the following question:

• What role do biomarkers play in quantifying the benefits and risks of therapy for prostate cancer patients? (Angelo A. Baccala, MD)
  • Briefly discuss the use of molecular biomarkers tests, such as Prolaris, in predicting the absolute benefit in risk of metastasis of ADT added to radiation therapy in newly diagnosed prostate cancer patients.